
ADC-, Bispecific Antibody–Based Therapies Help Build a New Treatment Paradigm in EGFR+ NSCLC
Following the September 2024 FDA approval of osimertinib (Tagrisso) in non–small cell lung cancer (NSCLC), investigators have been pursuing the development of combination approaches using the addition of the third-generation EGFR TKI and other targeted …